Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer

Shinkichi Takamori, Gouji Toyokawa, Isamu Okamoto, Kazuki Takada, Fumihiko Kinoshita, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Nobutaka Mukae, Fumihiko Hirai, Tetsuzo Tagawa, Yoshinao Oda, Toru Iwaki, Koji Iihara, Yoichi Nakanishi, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抜粋

Aim: To investigate the association between positivity for programmed cell death-ligand 1 (PD-L1) in brain metastases (BM) and the prognosis or clinical factors in patients with non-small cell lung cancer (NSCLC). Materials and Methods: Thirty-two patients with surgically resected brain-metastatic NSCLC were enrolled. The PD-L1 expression in BM was analyzed using the antibody against human PD-L1 (clone SP142). The PD-L1 positivity was defined as PD-L1 expression on brain-metastatic tumor cells of =5%. Results: Seven (21.9%) out of 32 patients showed PD-L1 positivity in BM. The PD-L1-positive BM group had a significantly shorter brain-specific disease-free survival than the PD-L1-negative BM group (p<0.05). PD-L1 positivity in BM was significantly associated with a heavy smoking history and the administration of radiotherapy for BM before surgery (p<0.05 and p<0.05, respectively). Conclusion: The PD-L1 expression in BM from NSCLC may be associated with local recurrence following surgery, and the smoking- or radiotherapy-derived effects.

元の言語英語
ページ(範囲)553-557
ページ数5
ジャーナルAnticancer research
38
発行部数1
DOI
出版物ステータス出版済み - 1 2018

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Takamori, S., Toyokawa, G., Okamoto, I., Takada, K., Kinoshita, F., Kozuma, Y., ... Maehara, Y. (2018). Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer. Anticancer research, 38(1), 553-557. https://doi.org/10.21873/anticanres.12258